Skip to main content
OpenTrials
Completed

NCT Number: NCT03023930

Opioid Use Disorder in the Emergency Department: CTN 0069

The purpose of this study is to evaluate the impact of (1) Implementation Facilitation (IF) on rates of provision of Emergency Department (ED)-initiated buprenorphine/naloxone (BUP) treatment with referral for ongoing medication-assisted treatment (MAT) and the (2) effectiveness of IF on patient engagement in formal addiction treatment at 30 days.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Johns Hopkins Hospital, Baltimore, Maryland, United States

Loading trial locations.

About this study

The study was originally proposed to use a Hybrid Type 3 Effectiveness-Implementation framework and a modified stepped wedge design.

Original protocol registration language: The study will be conducted at four EDs with a high prevalence of patients with untreated opioid use disorder (OUD). The four sites will receive the same sequence of evaluations and interventions: the baseline evaluation period after the standard dissemination practice, the IF phase, and continuation of facilitation into the IF evaluation period. The timing of initiation of the study activities at each site will be randomly offset by ~ 3 month increments to accommodate logistical constraints of simultaneous implementation at all sites. The study populations will include (1) ED providers and staff involved in the treatment of patients with OUD; (2) Community opioid treatment provider and program staff involved in providing care for patients with OUD referred from the ED; and (3) ED patients with moderate to severe OUD.

Exploratory analyses have been added to assess the impact of COVID-19 and social distancing guidance on drug use and drug supply; access to medications for opioid use disorder; and COVID19 disease from the perspectives of patient participants and ED leadership.

Upon results entry, changes were made to reflect that the study design originally was described as a "modified step wedge" but ultimately was not designed or implemented as such, as there was no substantial overlap of the baseline evaluation and IF evaluation periods. Thus, the statistical plan was adjusted accordingly.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Patient Inclusion Criteria:

  • Patients who are treated in the ED during study screening hours with Diagnostic and Statistical Manual (DSM)-5 criteria for moderate to severe OUD and provide an opioid positive urine sample will be eligible to participate.

Patient Exclusion Criteria:

  • Patients who test positive for fentanyl only are not eligible due to lack of uniformly available rapid urine tests.
  • Patients will be excluded if they have a medical or psychiatric condition requiring hospitalization at the index ED visit, are acutely suicidal or severely cognitively impaired precluding informed consent, present from an extended care facility, require continued prescription opioids for a pain condition, are a prisoner or in police custody at time of index ED visit, are currently (past 30 days) enrolled in formal addiction treatment including by court order, are unable to provide 2 contact numbers, are unwilling to follow study procedures, have been previously enrolled in the current study or do not speak English.

ED and Community Participants Inclusion Criteria:

  • ED and community providers and administrators (i.e. physicians, residents, fellows, nursing, nurse practitioners, physician assistants, pharmacists, social workers, counselors, administrative directors, office-based physicians and opioid treatment program representatives) as well as ED patients with OUD.

Treatment and study plan

Standard Dissemination Practice

Other

Emergency department provider education using a grand rounds format. The content of the lecture will cover the scope of the opioid problem, ED specific facts related to the epidemic, potential models of intervention including the results of publications outlining the efficacy of ED-initiated BUP.

Implementation Facilitation (IF)

Other

IF involves a "formative evaluation" to identify the specific and dynamic needs of stakeholders and the context for implementation of evidence-based practices. This evaluation informs the initial tailoring and refinement of the IF, which includes a bundle of services tailored to meet site-specific needs, such as identifying and engaging local stakeholders, providing extensive ongoing education, tailoring program to the site and monitoring performance and offering feedback.

Primary outcomes

  1. Implementation (Considered the Primary Outcome)

    Time frame: 12 months

    The primary implementation outcome will be evaluated assessing the rate of ED-initiated BUP therapy with referral for ongoing MAT

  2. Effectiveness

    Time frame: 30 Days Post Enrollment

    The primary effectiveness outcome is defined as the rates of patient engagement in formal addiction treatment on the 30th day post enrollment.

Secondary outcomes

  1. Implementation: ED Organizational Readiness to Change Assessment (ORCA) Score

    Time frame: Pre IF (Baseline)

    ED ORCA score relating to ED-initiated BUP with referral for ongoing MAT. Scores are dichotomized as less ready (scores 0-6) or most ready (scores 7-10).

Other outcomes

  1. Implementation: ED Provider Readiness and Preparedness Ruler Score

    Time frame: Pre IF (Baseline)

    ED provider readiness and preparedness ruler score to initiate BUP and provide referral for ongoing MAT.

  2. Implementation: ED Provider Readiness and Preparedness Ruler Score

    Time frame: post IF Evaluation Period (12 months)

    ED provider readiness and preparedness ruler score to initiate BUP and provide referral for ongoing MAT

  3. Implementation: ED Provider Readiness and Preparedness Ruler Score

    Time frame: Post IF (6 months)

    ED provider readiness and preparedness ruler score to initiate BUP and provide referral for ongoing MAT

  4. Effectiveness: Illicit Opioid Urine Toxicology

    Time frame: 30 days post enrollment

    Rates of illicit opioid negative urines

  5. Effectiveness: Healthcare Service Utilization

    Time frame: 30 days post enrollment

    All Healthcare Service Utilization Inpatient and Outpatient

  6. Effectiveness: Overdose Event

    Time frame: 30 days post enrollment

    Overdose event (past 30 days) captured by participant self-report, state medical examiner records, National Death Index and review of medical records

  7. Effectiveness: Opioid Use

    Time frame: 30 days post enrollment

    Self-reported days of illicit opioid use (past 7 days) as measured by Time-Line Follow-Back methods at 30 days

  8. Effectiveness: HIV Risk

    Time frame: 30 days post enrollment

    HIV risk taking behaviors (past 30 days) as measured by HIV Risk Taking Behavior Scale

  9. Implementation: Community ORCA Score

    Time frame: Pre IF (Baseline)

    Community opioid treatment provider/program ORCA score relating to receiving patients with OUD who have received ED-initiated BUP

  10. Implementation: Community ORCA Score

    Time frame: Post IF (6 months)

    Community opioid treatment provider/program ORCA score relating to receiving patients with OUD who have received ED-initiated BUP

  11. Implementation: Community ORCA Score

    Time frame: post IF Evaluation Period (12 months)

    Community opioid treatment provider/program ORCA score relating to receiving patients with OUD who have received ED-initiated BUP

  12. Implementation: Community Readiness and Preparedness Ruler Score

    Time frame: Pre IF (Baseline)

    Community opioid treatment provider/program readiness and preparedness ruler score to continue MAT for patients with OUD who have received ED-initiated BUP

  13. Implementation: Community Readiness and Preparedness Ruler Score

    Time frame: Post IF (6 months)

    Community opioid treatment provider/program readiness and preparedness ruler score to continue MAT for patients with OUD who have received ED-initiated BUP

  14. Implementation: Community Readiness and Preparedness Ruler Score

    Time frame: post IF Evaluation Period (12 months)

    Community opioid treatment provider/program readiness and preparedness ruler score to continue MAT for patients with OUD who have received ED-initiated BUP

  15. Implementation: ED Organizational Readiness to Change Assessment (ORCA) Score

    Time frame: Post IF (6 months)

    ED ORCA score relating to ED-initiated BUP with referral for ongoing MAT

  16. Implementation: ED Organizational Readiness to Change Assessment (ORCA) Score

    Time frame: Post IF Evaluation Period (12 months)

    ED ORCA score relating to ED-initiated BUP with referral for ongoing MAT

  17. Implementation: Fidelity

    Time frame: Baseline Period (Baseline)

    Fidelity will be measured using a critical action checklist relating to the provision of ED-initiated BUP with referral for ongoing MAT in eligible patients.

  18. Implementation: Fidelity

    Time frame: IF Evaluation Period (18 months)

    Fidelity will be measured using a critical action checklist relating to the provision of ED-initiated BUP with referral for ongoing MAT in eligible patients.

Sponsors and collaborators

Lead sponsor

Yale University

Other

Collaborators

  • National Institute on Drug Abuse (NIDA)
  • The Emmes Company, LLC

Registry information

Official study title

Opioid Use Disorder in the Emergency Department: Clinical Trials Network-0069

Important dates

Study start
2017
Primary completion
2021
Study completion
2022
First posted
Jan 18, 2017
Registry last updated
Dec 18, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.